Indeed, PPARs are currently therapeutic targets for NASH, though further research on combination of tissue-specific agonists/antagonists is needed to envisage the use of PPAR-targeted drugs for human metabolic disorders [50]. This evidence concerns the gene PPARA and metabolic dysfunction-associated steatohepatitis.